Efficacy of Methionine Restriction and the PARP-inhibitor Olaparib and Their Combination on<i>BRCA1</i>Mutant and Wild-type Triple-negative Breast Cancer Cell Lines
Methionine restriction and olaparib showed synergistic efficacy on the <i>BRCA1</i>-mutant TNBC cell line HCC1937. The BRCA1-mutant cell line MDA-MB-436 was most sensitive to rMETase. The <i>BRCA1/2</i> wild-type TNBC cell line MDA-MB-231 was sensitive to a methionine-free medium but resistant to olaparib. Therefore, methionine restriction has clinical potential for <i>BRCA1/2</i> wild-type and <i>BRCA1</i>-mutant olaparib-resistant and -sensitive TNBC.
Authors
- Hirokazu Tanino (ORCID: https://orcid.org/0000-0002-2675-1561)
- Sachiko Inubushi (ORCID: https://orcid.org/0000-0003-0541-4942)
- Robert M. Hoffman (ORCID: https://orcid.org/0000-0002-0049-0041)
- Tomonari Kunihisa (ORCID: https://orcid.org/0000-0003-2805-6746)
- Mayuko Miki
- SHOTARO INOUE
- Qinghong Han
Institutions
- Wakayama Medical University (JP)
- AntiCancer (United States) (US)
- Kobe University (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-03-28
- DOI
- https://doi.org/10.21873/anticanres.17522
- Citations
- 2
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 2.09